Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2BIOMEDICINE & PHARMACOTHERAPYIF7.52020-11-0195OAAI
Combining angiotensin receptor blockers with chlorthalidone or hydrochlorothiazide - which is the better alternative? A meta-analysis将血管紧张素受体阻滞剂与氯噻酮或氢氯噻嗪联合使用-哪个是更好的选择?荟萃分析SYSTEMATIC REVIEWSIF3.92020-08-245OAAI
EQ-5D-5L Bulgarian population normsEQ-5D-5L保加利亚人口规范EUROPEAN JOURNAL OF HEALTH ECONOMICSIF32020-08-1932PREAI
BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIAVALUE IN HEALTHIF62018-10-011OAAI
COMPARATIVE EFFECTIVENESS OF PAN-GENOTYPIC THERAPIES FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN BULGARIAVALUE IN HEALTHIF62018-10-010OAAI
COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIAVALUE IN HEALTHIF62018-10-010OAAI
COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIAVALUE IN HEALTHIF62018-05-010OAAI
COST-MINIMIZATION ANALYSIS OF TAFLUPROST/TIMOLOL MALEATE FOR LOWERING INTRAOCULAR PRESSURE (TOP) IN ADULT PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN BULGARIAVALUE IN HEALTHIF62018-05-010OAAI
BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIAVALUE IN HEALTHIF62018-05-010OAAI
BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIAVALUE IN HEALTHIF62018-05-010OAAI
BUDGET IMPACT ANALYSIS OF TAFLUPROST/TIMOLOL MALEATE FOR LOWERING INTRAOCULAR PRESSURE (TOP) IN ADULT PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN BULGARIAVALUE IN HEALTHIF62018-05-010OAAI
COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIAVALUE IN HEALTHIF62018-05-013PREAI
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysisDIABETOLOGY & METABOLIC SYNDROMEIF3.92017-11-1432OAAI
PLAQUE PSORIASIS IN BULGARIA: COMPARATIVE ANALYSIS AND HEALTH TECHNOLOGY ASSESSMENTVALUE IN HEALTHIF62017-10-010OAAI
ECONOMIC ANALYSIS AND EVALUATION OF THE VALUE OF THE PARALLEL EXPORT OF MEDICINAL PRODUCTS FOR TREATMENT OF ONCOLOGICAL DISEASES IN BULGARIA, 2016 T. VEKOV 1 AND G. KOLEV2VALUE IN HEALTHIF62017-10-010OAAI
COST-EFFECTIVENESS ANALYSIS OF VENETO CLAX FOR TREATMENT OF REFRACTORY/RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA WITH OR WITHOUT 17P DELETION IN BULGARIAVALUE IN HEALTHIF62017-10-011OAAI
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptinsDIABETOLOGY & METABOLIC SYNDROMEIF3.92015-07-162OAAI
PRICE CONTROL OF OUT-PATIENT CANCER DRUGS IN BULGARIA, 2010-2011: REFERENCE BASED PRICING AND PUBLIC TENDERS VERSUS REFERENCE BASED PRICING ONLYVALUE IN HEALTHIF62014-11-010OAAI
NATIONAL HEALTH INSURANCE FUND DRUG EXPENDITURE IN BULGARIA, 2007-2012: REFERENCE BASED PRICING ALONE OR IN COMBINATION WITH OTHER APPROACHES TO PRICINGVALUE IN HEALTHIF62014-11-010OAAI